Respiratory syncytial virus (RSV) vaccines in phase III clinical trials, in the approval process in older patients
| Manufacturer | Name | Vaccine type | Target group | Development status |
| Bavarian Nordic | MVA-BN RSV | Vector vaccine that produces five antigens from virus subtypes A and B, including RSV F and RSV G | Adults ≥60 years | Phase III |
| GSK | RSVPreF3 | Protein-based vaccine with genetically engineered antigen protein and adjuvant | Adults ≥60 years | FDA approval May 2023, European Commission approval June 2023 |
| Janssen | Ad26.RSV.preF-RSV | Vector vaccine resulting in production of pre-fusion RSV F protein | Adults ≥65 years | Phase III |
| Moderna | mRNA-1345 | mRNA vaccine leading to the production of pre-fusion RSV F protein | Adults ≥60 years | Phase III, intended for submission for approval in the second half of 2023 |
| Pfizer | RSV.preF | Protein-based vaccine, bivalent, with genetically engineered pre-fusion RSV F protein of virus subgroups A and B as antigens | Adults ≥60 years | Phase III, approval recommended by EMA in July 2023 |
EMA: European Medicines Agency; FDA: United States Food and Drug Administration; MVA: modified vaccinia Ankara.